Abstract 1463P
Background
Chemotherapy in combination with anti-PD-1/PD-L1 antibodies (chemoimmunotherapy) has become the standard treatment for advanced non-small cell lung cancer (NSCLC). Our previous studies highlighted that low baseline concentrations of IL-6 in plasma specimens or tumor tissues responded better to anti-PD-1/PD-L1 immunotherapy alone. However, the role of baseline IL-6 levels in predicting responses to chemoimmunotherapy and the development of resistance to chemoimmunotherapy has not been fully understood yet.
Methods
To confirm the predictive value of IL-6 in the baseline plasma, we conducted an enzyme-linked immunosorbent assay (ELISA) in a group of 123 advanced NSCLC patients who received chemoimmunotherapy. Next, we evaluated the role of IL-6 in chemoimmunotherapy resistance and the underlying mechanisms in mouse models of both lung adenocarcinoma and lung squamous cell carcinoma.
Results
Based on our cohort of 123 NSCLC patients, we found that patients with progressive disease had a higher baseline level of IL-6 in their plasma. Additionally, the potential predictive value of the baseline level of IL-6 in plasma samples for responses was confirmed with area under curve (AUC) up to 0.677. Patients with a low baseline concentration of IL-6 also had a longer progression-free survival and overall survival, with a cut-off value of 7.002 obtained from receiver operating characteristic curve (ROC). Meanwhile, univariate and multivariate Cox regression analyses revealed that baseline IL-6 level in plasma samples was an independent prognostic predictor. Further experiments in mouse models showed that overexpression of IL-6 weakened the anti-tumor effects of immunotherapy in combination with chemotherapy. Immunohistochemical studies also revealed that CD8+ T cells decreased while M2 macrophages, regulating T cells, and myeloid-derived suppressor cells infiltration increased in the IL-6 overexpressing group.
Conclusions
Our study highlights the potential of baseline IL-6 levels as a useful predictive biomarker for chemoimmunotherapy in NSCLC. IL-6 promotes an immunosuppressive tumor microenvironment, suggesting that targeting IL-6 could be a promising approach for cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20